#United States #New Orleans #Novo Nordisk #CagriSema #zenagamtide

Novo Nordisk Showcases Groundbreaking Data at 2026 ADA Conference

Novo Nordisk, a leader in healthcare dedicated to diabetes management, will unveil new data from its cardiometabolic portfolio at the 2026 Scientific Sessions of the American Diabetes Association (ADA) in New Orleans, from June 5 to 8, 2026. This anticipated event will highlight pivotal findings that support the efficacy and safety of novel treatments targeting type 2 diabetes and obesity.

The conference will feature results from the Phase 3 REIMAGINE 1-3 trials, focusing on CagriSema, a promising new combination of an amylin receptor agonist and a GLP-1 receptor agonist. These results are expected to provide insights on glycemic control and weight loss across various type 2 diabetes backgrounds. Additionally, data from zenagamtide, a novel GLP-1 and amylin receptor agonist currently in mid-stage trials, will be presented, further investigating its safety and efficacy profile.

Dr. Martin Lange, Executive Vice President of Research & Development and Chief Scientific Officer at Novo Nordisk, emphasized, "The ADA 2026 Scientific Sessions will showcase the depths of our commitment to addressing cardiometabolic diseases. Through innovative treatments and continued expansion of our successful portfolio, we aim to enhance the lives of those impacted by serious chronic conditions."

What to Expect at the ADA Sessions

Novo Nordisk will present a total of 40 abstracts during the sessions, covering extensive research on its investigational therapies, including the well-established semaglutide (marketed as Ozempic® and Wegovy®). Numerous studies will explore semaglutide's strong cardiometabolic profile, established through rigorous clinical frameworks.

Key Highlights of Presentations:

• - CagriSema will have presentations detailing its effect on appetite regulation and its relationship with brain activity in individuals with obesity, making substantial contributions to our understanding of metabolic health.
• - Zenagamtide will be highlighted for its potential impact on weight loss and metabolic markers in type 2 diabetes through innovative pharmacological mechanisms.
• - Additionally, new evidence regarding Ozempic® and Wegovy® will be shared, emphasizing their roles in improving health outcomes for various cardiometabolic conditions, including hypertension and associated comorbidities.

Investor Event and Future Directions

On June 7, 2026, during the conference, Novo Nordisk will host an event for investors, accessible via a live webcast. This meeting will delve into the scientific findings and abstracts presented, reflecting on the company's direction in advancing treatment for obesity and diabetes.

Novo Nordisk continues to advance its research and commitment to developing therapeutic options that not only treat but also aim to cure chronic diseases. As the global obesity epidemic escalates, with the CDC reporting millions affected by diabetes, the need for effective treatment solutions becomes increasingly critical.

The company maintains its long-term vision of pioneering advancements in diabetes care, supported by evidence-based approaches to drug development. Each breakthrough contributes to the foundation of patient care, focusing on tangible improvements in the quality of life for many.

About Novo Nordisk

Novo Nordisk, headquartered in Denmark, has over a century of experience in diabetes management. With operations in approximately 80 countries and a commitment to sustainable health innovation, the company aims to improve lives through medicinal advancements and established practices. Their ongoing research into cardiometabolic diseases, alongside innovative drug development, positions Novo Nordisk as a frontrunner in the global healthcare landscape. For further updates and information, please visit their official websites.

In conclusion, the 2026 ADA conference promises to be a significant event for healthcare professionals, researchers, and patients alike, as Novo Nordisk prepares to share crucial advancements in cardiometabolic health that may positively impact millions globally.